Profound Medical Corp. (PROF) bonds

PROFNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30

$7.44−0.41 (-5.22%)

Close on Nov 12, 2026Market cap $271.80MP/E –Yield –

Debt

Borrowings on the balance sheet, Sep 30, 2026

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

As tagged in Profound Medical's 10-Q for the period ended Mar 3, 2025

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.

Revolving credit lines and other committed borrowing capacity

Facility	Size
Senior secured revolving line of credit	$10.00M

Parsed from the XBRL in Profound Medical's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PROF.

Revenue growth65.3% · median -25.9%

Gross margin73.9% · median 44.2%

Operating margin-145.1% · median -39.5%

Net margin-137.5% · median -16.2%

Advertisement
300 × 250

See a number that looks wrong?